ENZN
Enzon Pharmaceuticals, Inc. · Healthcare
6.00
8.11%(+0.45)
Market OpenLast Updated: — ET
52W L: $0.0552W H: $12.99
$5.55
CHG+0.54 (+10.78%)
H$6.80
L$3.00
VOL3.2K
ENZN (1h)
Enzon Pharmaceuticals, Inc. · Healthcare
Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.10 and traded as high as $6.25. Enzon Pharmaceuticals shares last traded at $6.1916, with a volume of 1,584 shares traded. Enzon Pharmaceuticals Stock
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has completed its previously announced exchange offer to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon's common stock, $0.01 par value per share (the “Common Stock”). The offer and the withdrawal rights expired at 5:00 p.m., Eastern Time, on March 24, 2026. The offer was made pursuant to the Prospectus/Consent Solicitation/Offer to Exchange filed with the U.S. Securities and Exchange Commission on January 28, 2026 and declared effective on January 30, 2026 (the “Prospectus/Consent Solicitation/Offer to Exchange”).
CRANFORD, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that the previously approved 1-for-100 reverse stock split will become effective on March 24, 2026, at 4:30 pm, Eastern Time (the “Effective Time”), and the Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026. The Company's common stock is expected to trade under the temporary symbol “ENZND” for 20 trading days. As of the Effective Time, every one hundred (100) shares of the Company's issued and outstanding common stock will be combined into one (1) share of common stock. The par value per share of the Company's common stock will not change. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
CRANFORD, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon's common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires at 5:00 p.m., Eastern Time, on March 24, 2026, unless the offer is further extended.
CRANFORD, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon's common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires at 5:00 p.m., Eastern Time, on March 19, 2026, unless the offer is further extended.
CRANFORD, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon's common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires at 5:00 p.m., Eastern Time, on March 16, 2026, unless the offer is further extended.
WILLS STEPHEN T
director:
0 SH @ $0.00
2025-01-07
READ RANDOLPH C
director
84,550 SH @ $0.14
2023-06-16
READ RANDOLPH C
director
15,000 SH @ $0.13
2023-06-14
Firestone Jaffrey Adam
director:
0 SH @ $0.00
2022-06-09
COUCHMAN JONATHAN
10 percent owner
57,500 SH @ $0.39
2021-08-13
COUCHMAN JONATHAN
10 percent owner
50,000 SH @ $0.39
2021-08-13
READ RANDOLPH C
director
50,000 SH @ $0.16
2020-11-18
READ RANDOLPH C
director
50,450 SH @ $0.15
2020-11-16